Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must be willing and able to provide written informed consent.~2. BMI of \< 35 kg/m2~3. Patients experiencing one or more of functional dyspepsia symptoms beginning at least 6 months prior according to Rome III criteria, with the symptom(s) evident over the last 3 months at the time of screening~4. Patients with no evidence of organic lesions based on upper GI endoscopy, which could be the cause of dyspeptic symptoms~5. Women of childbearing potential (WOCBP) must have a negative pregnancy test result at the screening visit and use an adequate method of contraception to avoid pregnancy throughout the study~Exclusion Criteria:~1. Women who are pregnant or breastfeeding.~2. Women with a positive pregnancy test result on enrollment or prior to investigational product administration.~3. Subjects with a history of surgery that could affect gastrointestinal motility~4. Subjects with inflammatory bowel disease~5. Clinically significant chronic infection (eg. AIDS, etc), or significant medical or psychiatric illness.~6. Serious cardiovascular disease (including QT prolongation defined as QTc interval ≥ 450msec) or respiratory disease~7. History of alcohol or drug abuse within the previous one year.~8. Subjects with mental illness (e.g. schizophrenia, dementia etc) that may render the inability to complete the study~9. Physical and Laboratory Test Findings~10. Administration of any other investigational product or participation in other clinical trials within 3 months prior to randomization.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YH12852 0.1 mg (Type: EXPERIMENTAL): twice daily for 4 weeks
- YH12852 0.25 mg (Type: EXPERIMENTAL): twice daily for 4 weeks
- YH12852 0.5 mg (Type: EXPERIMENTAL): twice daily for 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): twice daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).